Figure 2.

Humoral immune response against SARS-CoV-2 spike after a third vaccine dose

(A–D) Total anti-RBD immunoglobulins (A) and pseudotyped neutralization assay against the ancestral SARS-CoV-2 variant G614 (B), and variants of concern Delta (C) and BA.1 sublineage of Omicron (D). Left panels in A, B, C, and D show the results for N- subjects whereas right panels show the results for N+ participants. Levels of immunoglobulins are reported in BAU/ml and neutralizing activity in neutralizing titer 50 (NT₅₀). All measures were summarized as geometric mean and 95% confidence interval. Ns: p > 0.05; ∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001.

See also Tables S1–S10.